Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Alessandro D. Santin, Michael J. Birrer, Stefania Bellone et al.|Gynecologic Oncology|2020Cited by 155
A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.Alessandro D. Santin, Michael J. Birrer, Wei Deng et al.|Journal of Clinical Oncology|2018Cited by 11